Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Xenon Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
Citi: Maintains Xenon Pharmaceuticals (XENE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $62.00 to $60.00.
Xenon Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Wedbush: Maintaining the Xenon Pharmaceuticals (XENE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $51.00 to $50.00.
Xenon Pharmaceuticals Analyst Ratings
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Xenon Pharmaceuticals Analyst Ratings
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk